Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Issue Section
Date
Availability
1-5 of 5
Keywords: Metastatic colorectal cancer
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Gerlinde Maria Michl, Florian M. Vogt, Andreas Nouriani, Roland Ladurner, Marcus Kremer, Timo Reisländer, Marlies Michl
Journal:
Chemotherapy
Chemotherapy (2024) 69 (1): 27–34.
Published Online: 19 June 2023
...Gerlinde Maria Michl; Florian M. Vogt; Andreas Nouriani; Roland Ladurner; Marcus Kremer; Timo Reisländer; Marlies Michl Trifluridine/tipiracil is approved for the use in later or last-line setting in previously treated metastatic colorectal cancer (mCRC) patients who progressed on standard anti...
Journal Articles
Ching-Wen Huang, Yung-Sung Yeh, Cheng-Jen Ma, Hsiang-Lin Tsai, Chao-Wen Chen, Ming-Yii Huang, Chien-Yu Lu, Jeng-Yih Wu, Jaw Yuan Wang
Journal:
Chemotherapy
Chemotherapy (2016) 62 (1): 80–84.
Published Online: 22 September 2016
...Ching-Wen Huang; Yung-Sung Yeh; Cheng-Jen Ma; Hsiang-Lin Tsai; Chao-Wen Chen; Ming-Yii Huang; Chien-Yu Lu; Jeng-Yih Wu; Jaw Yuan Wang Metastatic colorectal cancer (mCRC) combined with hyperbilirubinemia is typically considered a contraindication to irinotecan-based therapy, a proven first-line...
Journal Articles
Journal:
Chemotherapy
Chemotherapy (2015) 61 (1): 51–56.
Published Online: 04 November 2015
... in about 40-50% of these patients, and the liver is the most common site of distant spread [ 2 ]. For the last 40 years, the standard treatment for unresectable and/or metastatic colorectal cancer (mCRC) has been fluoropyrimidine-based systemic chemotherapy [ 3,4 ]. Oral fluoropyrimidines were shown...
Journal Articles
Hiroaki Nozawa, Takeshi Nishikawa, Toshiaki Tanaka, Junichiro Tanaka, Tomomichi Kiyomatsu, Kazushige Kawai, Keisuke Hata, Shinsuke Kazama, Hironori Yamaguchi, Soichiro Ishihara, Eiji Sunami, Joji Kitayama, Toshiaki Watanabe
Journal:
Chemotherapy
Chemotherapy (2015) 60 (5-6): 360–367.
Published Online: 22 September 2015
... in chemotherapy for metastatic colorectal cancer (mCRC). ‘Deepness of response' (DpR), defined as the maximum rate of reduction from the initial tumor burden, was recently proposed as a novel hypothetical parameter associated with overall survival (OS) in first-line chemotherapy plus cetuximab for mCRC. We...
Journal Articles
Markus Moehler, Frank Gutzler, Silke Steinmann, Michael Boehme, Ulrich Raeth, Wolfgang Stremmel, Peter R. Galle, Jochen Rudi
Journal:
Chemotherapy
Chemotherapy (2003) 49 (1-2): 85–89.
Published Online: 07 May 2003
... for metastatic colorectal cancer (CRC). Consequently, we compared toxicity, response and survival following two FA/5-FU regimens in 55 CRC patients refractory to bolus FA/5-FU. Methods: Twenty-eight patients (group A) received 5-FU (60 mg/kg body weight) for 48 h, and 27 (group B) received 2-hour infusions of FA...